Classifying for HER2 Dependence to De-Escalate Neoadjuvant Chemotherapy in Patients With HER2+ Early Breast Cancer Undergoing HER2 Double-Blockade

NCT06068985 · clinicaltrials.gov ↗

PHASE2

Phase

ACTIVE_NOT_RECRUITING

Status

63

Enrollment

OTHER

Sponsor class

Conditions

Breast Cancer
HER2-positive Breast Cancer

Interventions

DRUG: PHESGO

Sponsor

Latin American Cooperative Oncology Group

Collaborators

[object Object]
[object Object]